IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES

Author
Fu, T.
Ramchandren, R.
Witzig, T. E.
Zhang, L.
Besisik, Sevgi
Trneny, M.
Bravo, M. L. Casadebaig
Barnett, E.
Biyukov, T.
Goy, A.
Arcaini, L.
Williams, M. E.
Lamy, T.
Drach, J.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/30556
Collections